[Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report].
The patient was a 41-year-old women with platinum-refractory ovarian cancer. She received 135-210 mg/m2 paclitaxel for 13 cycles. She received granulocyte colony-stimulating factor (G-CSF) support to prevent severe granulocytopenia, and experienced little neurologic toxicity. Her quality of life was good throughout the prolonged period of use of paclitaxel.
Tanaka
H
H
Dept. of Obstetrics and Gynecology, Yamamoto Kumiai General Hospital.
Konishi
Y
Y
Saito
H
H
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002945:Cisplatin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011788:Quality of Life
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin